Overview

Biomarker Study of ATH434 in Participants With MSA

Status:
Not yet recruiting

Trial end date:
2024-11-15

Target enrollment:
0

Participant gender:
All

Summary

This study will assess the safety and efficacy of ATH434 in participants with a clinical diagnosis of Multiple System Atrophy

Phase:

Phase 2

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Alterity Therapeutics

Criteria

Inclusion Criteria:

1. Participant has clinical features of parkinsonism.

2. Participant has evidence of orthostatic hypotension and/or bladder dysfunction.

3. Participant has ataxia and/or pyramidal signs on neurological examination.

4. Participant has biomarker evidence of MSA in biologic fluid and on MRI.

Exclusion Criteria:

1. Participant is unable to swallow study drug.

2. Participant is unable to attend study visits or complete study procedures.

3. Participant has structural brain abnormality on MRI.

4. Participant has any significant neurological disorder other than MSA.

5. Participant has an unstable medical or psychiatric illness.

6. Participant has a contraindication to, or is unable to tolerate, MRI or lumbar
puncture.